Caplin Point Laboratories Limited (BOM: 524742)
India
· Delayed Price · Currency is INR
2,208.00
+3.40 (0.15%)
At close: Jan 20, 2025
Caplin Point Laboratories Revenue
Caplin Point Laboratories had revenue of 4.83B INR in the quarter ending September 30, 2024, with 17.81% growth. This brings the company's revenue in the last twelve months to 18.33B, up 16.86% year-over-year. In the fiscal year ending March 31, 2024, Caplin Point Laboratories had annual revenue of 16.96B with 15.51% growth.
Revenue (ttm)
18.33B
Revenue Growth
+16.86%
P/S Ratio
9.09
Revenue / Employee
5.38M
Employees
3,406
Market Cap
166.73B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 16.96B | 2.28B | 15.51% |
Mar 31, 2023 | 14.68B | 1.97B | 15.53% |
Mar 31, 2022 | 12.71B | 2.09B | 19.64% |
Mar 31, 2021 | 10.62B | 1.98B | 22.96% |
Mar 31, 2020 | 8.64B | 2.15B | 33.12% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,398.38B |
Tata Consultancy Services | 2,520.82B |
HDFC Bank | 2,761.06B |
Bharti Airtel | 1,554.78B |
ICICI Bank | 1,638.51B |
Infosys | 1,635.60B |
State Bank of India | 3,360.28B |
ITC Limited | 751.35B |
Caplin Point Laboratories News
- 4 days ago - Caplin Point Laboratories subsidiary gets USFDA nod for Levetiracetam in sodium chloride injection - Business Upturn
- 15 days ago - Caplin Point receives zero 483 observation from USFDA in recent inspection - Business Upturn
- 25 days ago - Stock Market Update, December 27: Oberoi Realty, Caplin Point Laboratories and Jubilant FoodWorks hit 52-week highs today - Business Upturn
- 5 weeks ago - Caplin Point gets USFDA approval for eye drops – Difluprednate Ophthalmic Emulsion - Business Upturn
- 7 weeks ago - Caplin Point Laboratories shares hit new 52-week high this week; Check details - Business Upturn
- 2 months ago - Caplin Point Laboratories shares up 2% after strong Q2 performance - Business Upturn
- 2 months ago - Caplin Point Laboratories Q2 FY25 Results: Revenue rises 17.8% YoY to ₹483.10 crore, net profit up 12.7% YoY - Business Upturn
- 3 months ago - Top losers today: NMDC, Tata Steel, Finolex, Caplin Point, JSW Steel, and Jindal Steel lead declines - Business Upturn